Oct 1 (Reuters) - CAMP4 Therapeutics Corp: * CAMP4 THERAPEUTICS INITIATES GLP TOXICOLOGY STUDIES FOR CMP-SYNGAP-01 Source text: Further company coverage: (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
